DESCRIPTION (provided by applicant): Cerebral small vessel disease (CSVD) is a common, progressive condition of aging, and a leading contributor to age-related disability due to stroke, cognitive decline, late-life onset depression and gait deterioration. In most cases the underlying vessel pathology can be classified as one of the two most common subtypes, arteriolosclerosis (AS) and cerebral amyloid angiopathy (CAA). Although classically recognized as white matter changes on MRI, CSVD frequently comes to clinical attention for the first time when a patient presents with intracerebral hemorrhage (ICH). Discovering the biological underpinnings of CSVD is a vital next step toward development of effective preventative strategies. Because their CSVD is uniformly severe, ICH survivors are ideal subjects in which to study CSVD and also form the group most likely to benefit from novel therapies. The proposed studies are motivated by the striking observation that ICH disproportionately affects African- American (AA) and Hispanic-American (HA) populations. Our preliminary analyses demonstrate that these differences extend to post-ICH risk for recurrent ICH, cognitive decline and late-life depression and that blood pressure (BP) may play a fundamental role in these differences. Our revised proposal, best titled "Longitudinal Follow-up of ICH Survivors in ERICH," will systematically determine whether 1) AA and HA are predisposed to CSVD of all types, 2) are predisposed solely to increased risk of AS, or 3) have no inherent predisposition but, through the effects of BP suffer more severe CSVD. To test the central hypothesis that discovering the mechanisms for this health disparity ICH will yield biological insights for CSVD, advance the search for treatments and have impact at the bedside, we propose to leverage the soon- to-conclude Ethnic/Racial Variations of ICH (ERICH) study to perform longitudinal follow-up of a cohort of 900 ICH survivors (300 each of AA, HA, and NHW), recruited in the last two years of ERICH, who have had neuroimaging, genetic, epidemiologic, and socio-ethnic variables ascertained at time of enrollment. Subjects will be followed by telephone every 6 months according to established and validated protocols.